EntryPoint Capital LLC Has $606,000 Position in Haemonetics Corporation $HAE

Key Points

• EntryPoint Capital LLC increased its stake in Haemonetics Corporation by 234.1% in the first quarter, now holding 9,536 shares valued at approximately $606,000.
• Citigroup Inc. raised its holdings in Haemonetics by 87.3%, while Voya Investment Management LLC boosted its stake by 820.5%, illustrating strong institutional interest, with institutional investors owning 99.67% of the company's stock.
• Analysts have mixed ratings for Haemonetics, with a consensus rating of "Moderate Buy" and an average price target of $85.18, reflecting varying investor outlooks on the company's performance.

EntryPoint Capital LLC raised its holdings in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 234.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 9,536 shares of the medical instruments supplier's stock after acquiring an additional 6,682 shares during the period. EntryPoint Capital LLC's holdings in Haemonetics were worth $606,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Voya Investment Management LLC increased its holdings in Haemonetics by 820.5% in the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after purchasing an additional 282,521 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Haemonetics by 9.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock worth $3,753,000 after buying an additional 4,217 shares during the period. Stifel Financial Corp increased its stake in shares of Haemonetics by 7.3% in the 4th quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier's stock valued at $1,154,000 after acquiring an additional 1,006 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Haemonetics by 434.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 314,067 shares of the medical instruments supplier's stock valued at $24,522,000 after acquiring an additional 255,338 shares during the last quarter. Finally, Hood River Capital Management LLC raised its position in shares of Haemonetics by 6.8% in the 4th quarter. Hood River Capital Management LLC now owns 214,290 shares of the medical instruments supplier's stock valued at $16,732,000 after acquiring an additional 13,710 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective for the company in a report on Wednesday, July 9th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a report on Friday, August 8th. Barrington Research dropped their price objective on Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Mizuho dropped their price target on Haemonetics from $90.00 to $70.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $85.18.

Haemonetics Stock Down 1.3%

Shares of NYSE:HAE traded down $0.7250 during midday trading on Monday, reaching $55.6450. The company had a trading volume of 210,066 shares, compared to its average volume of 810,649. The stock has a market cap of $2.68 billion, a PE ratio of 17.02, a P/E/G ratio of 1.04 and a beta of 0.40. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. Haemonetics Corporation has a 1-year low of $50.68 and a 1-year high of $94.99. The business's 50 day moving average price is $69.50 and its 200 day moving average price is $66.31.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $321.39 million during the quarter, compared to analysts' expectations of $305.12 million. During the same period last year, the business earned $1.02 earnings per share. The firm's revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Research analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.